Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
295 results
  • StatPearls: Almotriptan [BOOK]
    StatPearls. StatPearls Publishing: Treasure Island (FL)SidhuGursharanGAvalon University School of MedicinePreussCharles V.CVUniversity of South FloridaPatelPritiPUn of Florida College of PharmacyBOOK
  • Almotriptan is a medication used in the management and treatment of acute migraines. It is in the triptan 5-HT class of drugs. This activity reviews the indications, action, and contraindications for almotriptan as a valuable agent in treating and managing acute migraines. This activity will highlight the mechanism of action, adverse effects, and other vital factors such as dosing, pharmacodynami…
  • Drugs and Lactation Database (LactMed): Almotriptan [BOOK]
    Drugs and Lactation Database (LactMed). National Library of Medicine (US): Bethesda (MD)BOOK
  • There is minimal published experience with almotriptan during breastfeeding, although the dose in milk appears to be low. If almotriptan is required by the mother of an older infant, it is not a reason to discontinue breastfeeding, but until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
  • Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding. [Journal Article]
    Basic Clin Pharmacol Toxicol. 2021 Jun; 128(6):795-804.Amundsen S, Nordeng H, … Spigset O
  • Clinical data on the transfer of triptans into human breast milk remain scarce. In a lactation study including 19 breastfeeding women with migraine, we examined the excretion of six different triptans into milk. Following intake of a single dose, each participant collected seven breast milk samples at predefined intervals up to 24 hours after dose. Triptan concentrations in milk were measured usi…
  • Twenty-five years of triptans - a nationwide population study. [Journal Article]
    Cephalalgia. 2021 07; 41(8):894-904.Davidsson OB, Olofsson IA, … Hansen TF
  • The efficacy of triptans as the main acute treatment strategy for migraine headache at the population-wide level needs to be understood to inform clinical decision-making. We summarise key trends in triptan use using more than 25 years of Danish nationwide data.
  • Acute Treatments for Episodic Migraine [BOOK]
    Acute Treatments for Episodic Migraine. Agency for Healthcare Research and Quality (US): Rockville (MD)Singh RBH, VanderPluym JH, … Wang ZBOOK
  • CONCLUSIONS: A number of acute treatments for episodic migraine exist with varying degrees of evidence for effectiveness and harms. Use of triptans, NSAIDs, antiemetics, dihydroergotamine, CGRP antagonists, and lasmiditan is associated with improved pain and function. The evidence base for many other interventions for acute treatment, including opioids, remains limited.
  • Drugs for Acute Attack of Pediatric Migraine: A Network Meta-analysis of Randomized Controlled Trials. [Review]
    Clin Neurol Neurosurg. 2020 08; 195:105853.Wang G, Tan T, … Hong P
  • Migraine in pediatric is a common neurological disease, and its prevalence is varying widely. The medication for the acute attack of pediatric migraine is various. we take advantage of network meta-analysis to address the efficacy and rank of these medications. Database including Pubmed and Cochrane Library were queried using a specific searching strategy. The quality of trials enrolled was asses…
  • Mucoadhesive buccal film of almotriptan improved therapeutic delivery in rabbit model. [Journal Article]
    Saudi Pharm J. 2020 Feb; 28(2):201-209.Nair AB, Al-Dhubiab BE, … Shehata TM
  • Administration of almotriptan as an oral therapy is largely limited because of poor aqueous solubility and rather low bioavailability. The aim of present investigation was to formulate oral mucoadhesive film of almotriptan to improve the drug delivery and desired therapeutic effects. Placebo films (F1-F8) were prepared by varying the concentrations of Proloc 15 (7.5-15% w/v) and Eudragit RL 100/R…
  • Pattern of triptans use: a retrospective prescription study in Calabria, Italy. [Journal Article]
    Neural Regen Res. 2020 Jul; 15(7):1340-1343.Scuteri D, Adornetto A, … Corasaniti MT
  • Triptans are 5-hydroxytryptamine 1B/1D receptor agonists used in moderate to severe migraine attacks as first line when non-specific, symptomatic, nonsteroidal anti-inflammatory drugs are not effective. To gain insight in the treatment of migraine in the regional context, this retrospective (from January to August of the years 2017 and 2018) study aimed at monitoring the use of triptans approved …
  • Almotriptan: a review of 20 years' clinical experience. [Review]
    Expert Rev Neurother. 2019 08; 19(8):759-768.Pascual J, Vila C
  • Introduction: Almotriptan (ALT), a serotonin 5-HT1B/1D agonist has been used in the acute treatment of migraine with or without aura for 20 years, accumulating data on more than 15,000 patients in studies and from an estimated >150 million treated migraine attacks in daily clinical practice. The last major review of ALT was written almost 10 years ago. The current narrative review provides an ove…
  • Pharmacotherapy for acute migraines in children and adolescents. [Review]
    Expert Opin Pharmacother. 2019 03; 20(4):455-463.Barbanti P, Grazzi L, Egeo G
  • Migraine is increasingly recognized as an extremely burdensome and disabling disorder in both children and adolescents. A proper treatment plan is needed to improve the quality of life of both children and families as well as to minimize the risk of disease progression.
  • Menstrual Migraine and Treatment Options: Review. [Review]
    Headache. 2017 Feb; 57(2):194-208.Maasumi K, Tepper SJ, Kriegler JS
  • CONCLUSIONS: MM can be very difficult to treat. For acute treatments, rizatriptan has the best overall evidence. For short-term prevention, frovatriptan, zolmitriptan, or naratriptan, as well as magnesium, estrogen, naproxen sodium, or dihydroergotamine may be useful.
  • Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine. [Review]
    Drug Des Devel Ther. 2016; 10:3225-3236.Allais G, Benedetto C
  • Migraine is a common neurovascular disorder, affecting millions of people worldwide. Current guidelines recommend triptans as first-line treatment for moderate-to-severe migraine attacks. Frovatriptan is a second-generation triptan with a longer terminal elimination half-life in blood than other triptans (~26 hours). Three double-blind, randomized crossover preference studies have been recently c…
New Search Next